Figure 2.

Associations of sarcopenia, skeletal muscle index (SMI) loss, and dose‐limiting toxicities (DLTs). This figure displays the association of sarcopenia and skeletal muscle index loss with dose‐limiting toxicities during treatment with capecitabine + bevacizumab (CAP‐B) and capecitabine + oxaliplatin + bevacizumab (CAPOX‐B). Relative risks (RRs) are determined by Poisson regression models. All models were adjusted for age, sex, resection primary tumour, and dose reduction during initial capecitabine + oxaliplatin + bevacizumab treatment. ^*Statistically significant results.